262 related articles for article (PubMed ID: 8375022)
1. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
4. Bioreductive agents: a clinical update.
Boyer MJ
Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
[TBL] [Abstract][Full Text] [Related]
5. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
7. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Adams GE; Stratford IJ; Bremner JC; Edwards HS; Fielden EM
Radiother Oncol; 1991; 20 Suppl 1():85-91. PubMed ID: 2020774
[No Abstract] [Full Text] [Related]
8. Mechanism of oncogenicity for bioreductive drugs.
Hei TK; Piao CQ; He ZY; Hall EJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
11. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
12. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
13. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
14. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
Verweij J; Aamdal S; Schellens J; Koier I; Lund B
Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
[TBL] [Abstract][Full Text] [Related]
15. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
17. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
Smitskamp-Wilms E; Giaccone G; Pinedo HM; van der Laan BF; Peters GJ
Br J Cancer; 1995 Oct; 72(4):917-21. PubMed ID: 7547240
[TBL] [Abstract][Full Text] [Related]
18. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential.
Hei TK; He ZY; Piao CQ; Hall EJ
Radiat Res; 1990 Oct; 124(1 Suppl):S44-9. PubMed ID: 2236509
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive drugs and the selective induction of tumour hypoxia.
Bremner JC; Stratford IJ; Bowler J; Adams GE
Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]